Juvenile xanthogranuloma with hematological dysfunction treated with 2CDA-AraC.
Pediatr Blood Cancer
; 55(4): 757-60, 2010 Oct.
Article
en En
| MEDLINE
| ID: mdl-20589639
ABSTRACT
Juvenile xanthogranuloma was diagnosed in two infants aged 8 and 2 months with skin lesions, hepatosplenomegaly, and pancytopenia. Disease control was not achieved with first-line vinblastine-steroid-VP16 combination therapy. Two courses of 2-chlorodeoxyadenosine (2CDA) (0.3 mg/kg) and cytosine arabinoside (AraC) (1 g/m(2)) were then administered for 5 days and were followed, after hematological recovery, by maintenance therapy. Both patients had normal complete blood cell counts and no signs of JXG, respectively, 31 and 24 months after diagnosis.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Xantogranuloma Juvenil
/
Cladribina
/
Citarabina
/
Enfermedades Hematológicas
Límite:
Female
/
Humans
/
Infant
/
Male
Idioma:
En
Revista:
Pediatr Blood Cancer
Asunto de la revista:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Año:
2010
Tipo del documento:
Article
País de afiliación:
Francia